SEARCH:   Advanced

Blood, 1 February 2005, Vol. 105, No. 3, pp. 1102-1105. Prepublished online as a Blood First Edition Paper on October 5, 2004; DOI 10.1182/blood-2004-08-3253. This Article Full Text Full Text (PDF) All Versions of this Article: 2004-08-3253v1 105/3/1102    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Lisman, T. Articles by Rosendaal, F. R. Search for Related Content PubMed PubMed Citation Articles by Lisman, T. Articles by Rosendaal, F. R. Related Collections Hemostasis, Thrombosis, and Vascular Biology Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis Ton Lisman, Philip G. de Groot, Joost C.M. Meijers, and Frits R. Rosendaal From the Thrombosis and Haemostasis Laboratory, Department of Haematology, University Medical Centre, Utrecht, The Netherlands; Institute of Biomembranes, Utrecht University, Utrecht, The Netherlands; Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; and Department of Clinical Epidemiology and Haemostasis and Thrombosis Research Center, Leiden University Medical Center, Leiden, The Netherlands. The role of the fibrinolytic system in the development of deep vein thrombosis (DVT) is unclear. We determined the plasma fibrinolytic potential of patients enrolled in the Leiden Thrombophilia Study (LETS), a population-based case-control study on risk factors for DVT. Plasma fibrinolytic potential was determined in 421 patients and 469 control subjects by means of a tissue factor–induced and tissue-type plasminogen activator (tPA)–induced clot lysis assay. Using clot lysis times above the 70th, 80th, 90th, 95th, and 99th percentiles of the values found in control subjects as cut-off levels, we found a dose-dependent increase in risk for DVT in patients with hypofibrinolysis (odds ratios of 1.4, 1.6, 1.9, 2.1, and 2.2, respectively). This indicates a 2-fold increased risk of DVT in subjects with clot lysis times above the 90th percentile. The risk increase was not affected by age or sex (adjusted odds ratio for 90th percentile, 2.0), and after correction for all possible confounders (age, sex, and levels of procoagulant proteins shown to associate with clot lysis times in the control population), the risk estimate was marginally reduced (odds ratio, 1.6 for 90th percentile). Taken together, these results indicate that plasma hypofibrinolysis constitutes a risk factor for venous thrombosis, with a doubling of the risk at clot lysis times that are present in 10% of the population. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. M. Carter, C. M. Cymbalista, T. D. Spector, P. J. Grant, and on behalf of the EuroCLOT Investigators Heritability of Clot Formation, Morphology, and Lysis: The EuroCLOT Study Arterioscler. Thromb. Vasc. Biol., December 1, 2007; 27(12): 2783 - 2789. [Abstract] [Full Text] [PDF] J. A. Heit Thrombophilia: Common Questions on Laboratory Assessment and Management Hematology, January 1, 2007; 2007(1): 127 - 135. [Abstract] [Full Text] [PDF] G. Cesarman-Maus, N. P. Rios-Luna, A. B. Deora, B. Huang, R. Villa, M. d. C. Cravioto, D. Alarcon-Segovia, J. Sanchez-Guerrero, and K. A. Hajjar Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome Blood, June 1, 2006; 107(11): 4375 - 4382. [Abstract] [Full Text] [PDF] J. K. Hennan, H. Elokdah, M. Leal, A. Ji, G. S. Friedrichs, G. A. Morgan, R. E. Swillo, T. M. Antrilli, A. Hreha, and D. L. Crandall Evaluation of PAI-039 [{1-Benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic Acid], a Novel Plasminogen Activator Inhibitor-1 Inhibitor, in a Canine Model of Coronary Artery Thrombosis J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 710 - 716. [Abstract] [Full Text] [PDF] W. Sturm, A. Sandhofer, C. J.M. Doggen, N. L. Smith, R. N. Lemaitre, S. R. Heckbert, F. R. Rosendaal, and B. M. Psaty Dyslipidemia and Thrombosis: Causal Relationship or Epiphenomenon of Sedentary Lifestyle? Arterioscler. Thromb. Vasc. Biol., March 1, 2005; 25(3): e19 - e19. [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020